Increased holdings by hedge funds, speculations on M&A interests, and strong demand for GLP-1 therapies, are catalysts that could send shares higher.

Our target potential upside is 19%-31% in the next 3-6 months.

An industry leader, robust fundamentals combined with an appealing technical trend certainly justify adding shares to the mix.

And it’s telling us that this bull market isn’t over.

After a stellar earnings report, design wins are piling up and guidance points to sustained growth.

In short, the conflict in the Middle East is disrupting various markets. If you don’t own commodities yet, consider adding some exposure to your portfolio today.

Our target potential upside is 33%-57% in the next 3-6 months.